A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 21 May 2016
At a glance
- Drugs PA83 FhCMB (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors Fraunhofer USA Center for Molecular Biotechnology
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2015 Status changed from recruiting to active, no longer recruiting,as reported by ClinicalTrials.gov.
- 17 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.